Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030

Intent to start at least 5 innovative Phase 3 vaccine programs by 2025

AstraZeneca announces US$400 million investment in reforestation and biodiversity

New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia

Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide shows nearly 19% weight loss in people with obesity

Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite

Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction

Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program

USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata

LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12

Ipca Laboratories receives 8 observations from USFDA

The company will submit its comprehensive response on these observations to the USFDA

Eugia Pharma signs voluntary license with Medicines Patent Pool to develop generic version of Nilotinib Capsules

The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India

Fortis Healthcare to divest its Vadapalani, Chennai Hospital business operations to Kauvery Group of Hospitals

Elekta Unity MR Linac revolutionizes cancer care in India

LVPEI raises awareness on antimicrobial resistance among medical students

Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety